349 related articles for article (PubMed ID: 14575823)
21. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
Roach M; Hanks G; Thames H; Schellhammer P; Shipley WU; Sokol GH; Sandler H
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):965-74. PubMed ID: 16798415
[TBL] [Abstract][Full Text] [Related]
22. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
23. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
Aref I; Eapen L; Agboola O; Cross P
Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
[TBL] [Abstract][Full Text] [Related]
24. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
Vicini FA; Kestin LL; Martinez AA
Cancer; 2000 May; 88(10):2305-18. PubMed ID: 10820353
[TBL] [Abstract][Full Text] [Related]
25. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
26. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
27. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A
J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
30. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
31. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
32. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology.
Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):559-66. PubMed ID: 10701734
[TBL] [Abstract][Full Text] [Related]
33. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
34. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
35. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
36. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
Critz FA
J Urol; 2002 Mar; 167(3):1310-3. PubMed ID: 11832720
[TBL] [Abstract][Full Text] [Related]
37. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
38. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
39. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
[TBL] [Abstract][Full Text] [Related]
40. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
Amling CL; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
J Urol; 2001 Apr; 165(4):1146-51. PubMed ID: 11257657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
